Trombocitopenia inducida por heparina de bajo peso molecular
Barra lateral del artículo
Descargas
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Contenido principal del artículo
Resumen
Se presentan dos casos de trombocitopenia inducida por heparina de bajo peso molecular, confirmados clínica y serológicamente, manejados con fondaparinux.
Citas
Warketing TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin- induced thrombocytopenia: American College of Chest physicans evidence based clinical practice guidelines. Chest. 2008; 6 (Suppl):340s-80s.
Cuker A. Recent advances in heparin-induced thrombocytopenia. Curr Opin Hematol. 2011 Sep; 18(5):315-22.
Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost. 2011; 9:105–117.
Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with lowmolecular-weight heparin or unfractionated heparin. N Engl J Med. 1995 May 18; 332(20):1330-5.
Hong MS, Amanullah AM. Heparin-induced thrombocytopenia: a practical review. Rev Cardiovasc Med. 2010; 1(1):13-25.
Levy J, Hursting M. Heparin induced thrombocytopenia, a potrombotic disease. Hematol Oncol Clin North Am. 2007; 21:65-68.
Pouplard C, Amiral J, Borg JY, Laporte- Simitsidis S, Delahousse B, Gruel Y. Decision analysis for use of platelet aggregation test, carbon serotonin release assay, and heparin-platelet factor 4 enzyme- linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1999; 111:700-6.
Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997; 127:804–812.
Srinivasan AF, Rice L, Bartholomew JR, Rangaswamy C, La Perna L, Thompson JE, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med. 2004; 164:66–70.
Greinacher A. Lepirudin for the treatment of heparininduced thrombocytopenia. In: Warketin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 3. ed. New York, NY: Marcel Dekker; 2004. p. 397–436.
Chong BH, Magnani HN. Danaparoid for the treatment of heparininduced thrombocytopenia: an overview. In: Warketin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 3. ed. New York, NY: Marcel Dekker; 2004:p.371–396.
Beck A, Oertel M, Valgus J. Fondaparinux and the management of heparin induced thrombocytopenia: the journey continues. Am Pharmacother. 2009; 43: 1636-46.
Efird L, Kockler D. Fondaparinox for treatment and prophylaxis of heparin induced thrombocytopenia. Am Pharmacother. 2006; 30:1383-87.
Dager W, Andersen J, Nutescu E. Special considerations with fondaparinux therapy: heparin induced thrombocytopenia and wound Healing. Pharmacotherapy. 2004; 24:88s-94s.
Ahmad S, Jeske WP, Walenga JM, Hoppensteadt DA, Wood JJ, Herbert JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost. 1999; 5:259–66.
Warkentin TE. Agents for the treatment of heparininduced thrombocytopenia. Hematol Oncol Clin North Am. 2010; 24: 755–75.
Shaikh N. Heparin-induced thrombocytopenia. J Emerg Trauma Shock. 2011; 4(1):97-102.
Papadopoulus S, Flynn JD, Lewis DA. Fondaparinux as a treatment option for the heparin induced thrombocytopenia. Pharmoterapy. 2007; 27:921-26